☆ 4.8 Article

Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022

Lamprini Veneti et al.

Summary: A study found that the Omicron variant of COVID-19 has a 73% reduced risk of hospitalization compared to the Delta variant. Omicron cases who had received two doses of the vaccine 7-179 days before diagnosis had a lower risk compared to Delta (66% vs 93%), while those who received three doses had a similar risk reduction (86% vs 88%).

EUROSURVEILLANCE (2022)

Add to Collection

Article Medicine, General & Internal

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Emma K. Accorsi et al.

Summary: Assessing the performance of COVID-19 vaccines against the Omicron variant is crucial for public health guidance. This study found that receiving three doses of mRNA COVID-19 vaccine was associated with a lower likelihood of symptomatic SARS-CoV-2 infection compared to being unvaccinated or receiving two doses. These findings suggest that three doses of mRNA vaccine provide protection against both Omicron and Delta variants, though the protection against Omicron may be slightly lower.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

Paul R. Wratil et al.

Summary: This study reports on the dynamics of neutralizing antibodies in individuals convalescing from coronavirus disease 2019 or who are vaccine-naive and subsequently vaccinated. The findings suggest that infection-plus-vaccination-induced hybrid immunity or triple immunization can induce high-quality antibodies with superior neutralization capacity against variants of concern, including omicron.

NATURE MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

Samuel M. S. Cheng et al.

Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.

NATURE MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021

Amelia G. Johnson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Microbiology

Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection

Yang Yang et al.

Summary: Understanding the dynamics of neutralizing antibody responses in COVID-19 convalescents is crucial for controlling the pandemic and guiding vaccination strategies. This study showed that neutralizing antibody titers in COVID-19 convalescents peaked around 120 days after illness onset and subsequently declined, but detectable levels of antibodies were still present in most convalescents after 400-480 days.

NATURE MICROBIOLOGY (2022)

Add to Collection

Article Immunology

Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients

Corine H. GeurtsvanKessel et al.

Summary: This study demonstrates that vaccinated individuals retain T cell immunity to the SARS-CoV-2 Omicron variant, despite low levels of neutralizing antibodies. Booster vaccinations can partially restore cross-neutralization of the Omicron variant.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Infectious Diseases

The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers

Etienne Racine et al.

Summary: Among unvaccinated healthcare workers, reinfection with SARS-CoV-2 following a primary infection remained rare. The duration of seropositivity was significantly longer in symptomatic individuals compared to asymptomatic ones.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Rebecca P. Payne et al.

Summary: The study demonstrates that the first dose of the BNT162b2 mRNA vaccine can induce protection against the B.1.1.7 variant within weeks, and extending the interval between doses can result in higher levels of neutralizing antibody response. Prior infection with the virus can accelerate the immune response.

CELL (2021)

Add to Collection

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccines

C. Buddy Creech et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Add to Collection

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Microbiology

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Alexandra Tauzin et al.

Summary: A single dose of the BNT162b2 mRNA vaccine can be up to 90% effective, with boosted humoral and T cell responses in previously infected individuals. Therefore, spacing doses may help vaccinate more people in conditions of limited vaccine supply.

CELL HOST & MICROBE (2021)

Add to Collection

Article Immunology

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Mark M. Painter et al.

Summary: The study found that after SARS-CoV-2 mRNA vaccination, CD4(+) T cell responses in naïve individuals were fast, while CD8(+) T cell responses developed gradually. Th1 and Tfh cell responses after the first dose were correlated with post-boost CD8(+) T cells and neutralizing antibodies.

IMMUNITY (2021)

Add to Collection

Letter Medicine, General & Internal

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Madhumita Shrotri et al.

LANCET (2021)

Add to Collection

Article Cell Biology

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

Daniel Lozano-Ojalvo et al.

Summary: The study found that the second dose of the vaccine increases immunity in naive individuals, while those who previously recovered from COVID-19 reach their peak immunity after the first dose. This suggests that a second dose may not be necessary for individuals who have been infected with SARS-CoV-2 before.

CELL REPORTS (2021)

Add to Collection

Article Medicine, Research & Experimental

One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19

Riccardo Levi et al.

Summary: A study showed that individuals with prior exposure to SARS-CoV-2 had a significant increase in antibody response within 5 to 18 days after receiving the Pfizer/BioNTech vaccine. Symptomatic individuals reached a high titer of antibodies with just one dose, suggesting that a second dose may not be necessary.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19

Alessio Mazzoni et al.

Summary: The study suggests that COVID-19-recovered individuals may not need a second vaccine dose to further enhance immune response, while naive individuals require a second dose for increased immunity. This indicates that redirecting vaccine doses from COVID-19-recovered individuals to naive individuals could shorten the time to achieve herd immunity.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Qun Li et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Article Microbiology

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

Alba Grifoni et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat et al.

NATURE MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

Add to Collection

Article Microbiology

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Jeffrey Seow et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Virology

A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets

Mariana Baz et al.

JOURNAL OF VIROLOGY (2015)

Add to Collection

Article Multidisciplinary Sciences

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Insaf Salem Fourati et al.

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.